Arca
Skip to content
Tools
Tools

PIK3CG: Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform

Phosphoinositide-3-kinase (PI3K) that phosphorylates PtdIns(4,5)P2 (Phosphatidylinositol 4,5-bisphosphate) to generate phosphatidylinositol 3,4,5-trisphosphate (PIP3).

  • Drugs that act on it: 5
  • Approved: 1
  • In phases 1 to 3: 4
  • Sponsors: 5

Who is on it, and how far along

Every drug ChEMBL records acting on PIK3CG, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule 4
  • Other 1

Approved1

  • Duvelisib

Phase 30

    Phase 23

    • Eganelisib
    • Tenalisib
    • TG100-115

    Phase 11

    • CAL-263

    Sponsors

    Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.

    • Rhizen Pharmaceuticals SA120%
    • Stelexis BioSciences120%
    • TargeGen120%

    The landscape

    Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. All act as: PI3-kinase p110-gamma subunit inhibitor.
    DuvelisibBoxed warningApprovedSecura BioSmall moleculeInhibitor15
    EganelisibPhase 2Stelexis BioSciencesSmall moleculeInhibitor2
    TenalisibPhase 2Rhizen Pharmaceuticals SASmall moleculeInhibitor1
    TG100-115Phase 2TargeGenSmall moleculeInhibitor0
    CAL-263Phase 1Gilead SciencesOtherInhibitor0

    Open trials

    The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 11 in all, from ClinicalTrials.gov.
    A Study of Topical Duvelisib in Participants With Early-stage Mycosis FungoidesDuvelisibPhase 1Not yet recruitingSecuraBioJul 20, 2026
    Assessing PI3K Gamma Inhibition With Azacitidine, Venetoclax and Eganelisib in Patients With Acute Myeloid LeukemiaEganelisibPhase 1RecruitingJacqueline Garcia, MDFeb 27, 2026
    Duvelisib Maintenance for the Treatment of Peripheral T-Cell LymphomasDuvelisibPhase 2RecruitingCity of Hope Medical CenterDec 19, 2025
    A Study of Alectinib and Duvelisib in People With Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma (ALK+ALCL)DuvelisibPhase 1RecruitingMemorial Sloan Kettering Cancer CenterJun 3, 2025
    Duvelisib and Venetoclax in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)DuvelisibPhase 1 / Phase 2RecruitingJonsson Comprehensive Cancer CenterFeb 6, 2025
    Eganelisib as Monotherapy and in Combination With Cytarabine in Relapsed/Refractory AML/HR-MDS and in Combination With Azacitidine in Previously Untreated HR-MDSEganelisibPhase 1RecruitingStelexis BioSciencesAug 1, 2024
    PI3K Inhibitors for the Treatment of Relapsed/Refractory Indolent T/NK-cell LymphomasDuvelisibPhase 2RecruitingInstitute of Hematology & Blood Diseases Hospital, ChinaJul 31, 2024
    A Study of Duvelisib Versus Gemcitabine or Bendamustine in Participants With Relapsed/Refractory Nodal T Cell Lymphoma With T Follicular Helper (TFH) PhenotypeDuvelisibPhase 3RecruitingSecuraBioJul 26, 2024
    Efficacy and Safety of Tenalisib in Patients With Metastatic Triple Negative Breast Cancer (TNBC)TenalisibPhase 2RecruitingRhizen Pharmaceuticals SAJan 3, 2024
    Prospective, Single Arm, Single Center Study of Duvelisib Combined With Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma (PTCL)DuvelisibPhase 2RecruitingLiling ZhangAug 4, 2023
    (CHANT)Real World Study of Duvelisib in the Treatment of Non-Hodgkin's Lymphoma (NHL)Duvelisib—Not yet recruitingRuijin HospitalJun 28, 2023

    Diseases most associated with it

    Open Targets association score, 0 to 1; all associations
    • Immunodeficiency 72 with autoinflammation0.55
    • Immunodeficiency 97 with autoinflammation0.53
    • Hypertensive disorder0.47
    • Neoplasm0.44
    • Neoplasm of mature B-cells0.43
    • Cancer0.41
    • Head and neck squamous cell carcinoma0.32

    Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL3267, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. Gene name, function (UniProt P48736, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

    Esc

    Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

    Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.